<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Lanadelumab_Submission_DiseaseStateOverview_Q10</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Lanadelumab/berotralstat will not be used in combination with other medications used for long-term prophylactic treatment of angioedema (e.g., concurrent C1-INH, lanadelumab and/or berotralstat use). However, in cases of switching, short-term concurrent use is permitted to provide adequate prophylactic coverage while lanadelumab/berotralstat reaches steady state levels in the patient</questionText>
        <status>Active</status>
        <versionNumber>2</versionNumber>
    </assessmentQuestionVersion>
    <dataType>Checkbox</dataType>
    <developerName>Lanadelumab_Submission_DiseaseStateOverview_Q10</developerName>
    <name>Lanadelumab_Submission_DiseaseStateOverview_Q10</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
